Please find the enclosed intimation of the Company as per the captioned subject for your reference.

November 2, 2026 The Manager- Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400 001 The Manager- Listing National Stock Exchange of India Limited Exchange Plaza, Bandra – Kurla Complex, Bandra (E), Mumbai – 400 051 Dear Sir/Madam, Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update This is pursuant to Regulation 30(7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our communication dated July 30, 2026, in connection with the notice received on July 29, 2026 (‘Notice’) issued by the National Pharmaceutical Pricing Authority (‘NPPA’) for alleged overcharging under the Drugs (Prices Control) Order, 2013 (‘DPCO, 2013’) in relation to Symbicort Turbuhaler 160/4.5 (Inhaler). We hereby inform that, the Hon'ble High Court of Delhi, vide its order dated October 29, 2026 (‘Order’), has directed that no coercive steps be taken by NPPA in this matter, until the next date of hearing, listed on January 11, 2027. Further, please find the details as required under the SEBI Master Circular HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 attached herewith as Annexure – A. Kindly take the above information on record. Thanking You, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No.: A25784 Annexure – A Sl. No. Particulars Details 1. Name of the authority Hon'ble High Court of Delhi 2. Nature and details of the action(s) Order directing NPPA that no coercive steps be taken by NPPA in this matter, until the next date of hearing i.e. January 11, 2027 3. Date of receipt of direction or order, October 30, 2026 including any ad-interim or interim orders, or any other communication from the authority 4. Details of the Further to a show cause notice dated September 11, violation(s)/contravention(s) committed 2025, the Company had received the abovementioned or alleged to be committed Notice from NPPA and a subsequent reminder, alleging overcharging in connection with Symbicort Turbuhaler 160/4.5 (Inhaler) for the period from May 2016 to November 2025 under DPCO, 2013. The Company challenged the demand before the Hon'ble High Court of Delhi. Vide its Order, the Hon'ble High Court has directed that no coercive steps be taken by NPPA till the next date of hearing i.e. listed on January 11, 2027. 5. Impact on financial, operation or other The Order directs that NPPA cannot take coercive activities of the listed entity, steps till the next hearing date, to recover Rs. quantifiable in monetary terms to the 151,19,66,035/- approximately, comprised of alleged extent possible overcharged amount and interest upto 30th October, 2026.